Shenzhen Weiguang Biological Products (002880) Fundamentals 2026 — P/E 19.2x, Revenue Analysis | SniperIQ
Shenzhen Weiguang Biological Products (002880) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥4.5B, trading at ¥19.78 on the SHZ. This SniperIQ fundamentals page covers Shenzhen Weiguang Biological Products's valuation (P/E 19.2x, P/B 1.8x), profitability (net margin 18.5%), revenue (¥1.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen Weiguang Biological Products's market cap?
Shenzhen Weiguang Biological Products (002880) has a market capitalization of approximately ¥4.5B, trading at ¥19.78 on the SHZ. Market cap moves with the live share price.
What is Shenzhen Weiguang Biological Products's P/E ratio?
Shenzhen Weiguang Biological Products's trailing twelve-month P/E ratio is 19.2x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen Weiguang Biological Products?
Shenzhen Weiguang Biological Products runs a net profit margin of 18.5%, a gross margin of 38.8%, and an operating margin of 21.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen Weiguang Biological Products generate?
Shenzhen Weiguang Biological Products reported revenue of ¥1.3B for fiscal year 2025, with net income of ¥246M and earnings per share (EPS) of 1.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen Weiguang Biological Products pay a dividend?
Shenzhen Weiguang Biological Products offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen Weiguang Biological Products financially healthy?
Shenzhen Weiguang Biological Products carries a debt-to-equity ratio of 0.31x and a current ratio of 2.36x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen Weiguang Biological Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen Weiguang Biological Products (002880) the key facts are: market cap ¥4.5B, P/E 19.2x, revenue ¥1.3B, 52-week range 19.25-33.79. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen Weiguang Biological Products's full fundamentals live
Get Shenzhen Weiguang Biological Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.